

Exatecan (Mesylate)

Catalog No: tcsc2952

Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Specifications

CAS No:

169869-90-3

Formula:

 $\mathrm{C_{25}H_{26}FN_{3}O_{7}S}$

Pathway: Cell Cycle/DNA Damage

Target:

Topoisomerase

Purity / Grade:

Solubility:

DMSO : 15.3 mg/mL (28.78 mM; Need ultrasonic and warming); H2O : 6 mg/mL (11.29 mM; Need ultrasonic and warming)

Alternative Names: DX8951f

Observed Molecular Weight:

531.55

Copyright 2021 Taiclone Biotech Corp.



Product Description

Exatecan Mesylate is a water soluble **topoisomerase I** inhibitor, with an **IC**₅₀ of 2.2 μ M (0.975 μ g/mL), and can be used in cancer research.

IC50 & Target: IC50: 2.2 µM (topoisomerase I)^[1]

In Vitro: Exatecan Mesylate is a potent topoisomerase I inhibitor, with an IC₅₀ of 0.975 µg/mL. Exatecan Mesylate (DX-8951f) significantly inhibits the proliferation of several cancer cell lines, with mean GI_{50} s of 2.02 ng/mL, 2.92 ng/mL, 1.53 ng/mL, and 0.877 ng/mL for breast cancer cells, colon cancer cells, stomach cancer cells and lung cancer cells, respectively^[1]. Exatecan Mesylate (DX-8951f) displays cytotoxic activities against PC-6, PC-6/SN2-5 cells, with mean GI_{50} s of 0.186 and 0.395 ng/mL, respectively. Exatecan Mesylate (34 nM) stabilizes DNA-Topol complexes in PC-6 and PC-6/SN2-5 cells^[3].

In Vivo: Exatecan Mesylate (DX-8951f, 3.325-50 mg/kg, i.v.) exhibits antitumor activities in the mice model bearing tumor cells, without toxic death^[1]. Exatecan Mesylate (15, 25 mg/kg, i.v.) hightly inhibits MIA-PaCa, BxPC-3 primary tumor growth in the MIA-PaCa-2 early-stage model and early-stage model of BxPC-3. Exatecan Mesylate (15, 25 mg/kg, i.v.) also significantly suppresses BxPC-3 lymphatic metastasis and completely eliminates lung metastasis in the BxPC-3 late-stage cancer model^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.